42.0.0.26 – Redirect Fix (Removed pre-redirect output)
DEBUG LOG – klik om te openen
=== VARIABELEN ===
Array
(
    [defid] => VWS-WOO-08-1245881
    [request_id] => 
)

=== SQL LOG ===
Geen SQL queries.
Huidig document record
Array
(
    [id] => a54eae5e-7c83-4b3b-9b5f-2ec8c439adfb
    [Document ID] => 1245881
    [Document naam] => AEs na AstraZeneca.docx
    [Bestandsnaam] => 
    [Beoordeling] => 
    [Beoordelingsgrond] => 
    [Toelichting] => 
    [Publieke link] => 
    [Locatie open.minvws.nl] => https://open.minvws.nl/dossier/VWS-WOO/3661708-1052463-pdo/document/VWS-WOO-08-1245881
    [Opgeschort] => 
    [Definitief ID] => VWS-WOO-08-1245881
    [Status] => 
    [FromFile] => https://open.minvws.nl/dossier/VWS-WOO/3661708-1052463-pdo
    [DocumentPublicationDate] => 11 maart 2021
    [DocumentStatusCheckedDate] => 
    [DocumentStatusCheckedResult] => 
    [SourceFileType] => 
    [Tags] => 
    [Besluit] => 
    [ModifiedDate] => 2025-09-22 08:10:46
    [DeletedDate] => 
    [BesluitURL] => 
    [CreatedDate] => 2025-06-19 18:31:59
    [DocumentDownloadLink] => 
    [DigestLaatsteControleDatum] => 2025-09-22 08:10:46
)

Document: VWS-WOO-08-1245881

Pagina 1 preview
Klik om te vergroten

Document correcties

Geregistreerde datum: 20210311

Geregistreerde documentnaam: AEs na AstraZeneca.docx

Document metadata

Metadata tonen (25 velden)
VeldWaarde
ida54eae5e-7c83-4b3b-9b5f-2ec8c439adfb
Document ID1245881
Document naamAEs na AstraZeneca.docx
Bestandsnaamleeg!
Beoordelingleeg!
Beoordelingsgrondleeg!
Toelichtingleeg!
Publieke linkleeg!
Locatie open.minvws.nlhttps://open.minvws.nl/dossier/VWS-WOO/3661708-1052463-pdo/document/VWS-WOO-08-1245881
Opgeschortleeg!
Definitief IDVWS-WOO-08-1245881
Statusleeg!
FromFilehttps://open.minvws.nl/dossier/VWS-WOO/3661708-1052463-pdo
DocumentPublicationDate11 maart 2021
DocumentStatusCheckedDateleeg!
DocumentStatusCheckedResultleeg!
SourceFileTypeleeg!
Tagsleeg!
Besluitleeg!
ModifiedDate2025-09-22 08:10:46
DeletedDateleeg!
BesluitURLleeg!
CreatedDate2025-06-19 18:31:59
DocumentDownloadLinkleeg!
DigestLaatsteControleDatum2025-09-22 08:10:46

🧙 User tags

Nog geen user tags

Document attributen

TagWaardeDatum
document_SectionDownloadButton12025-09-01 12:32:56
About_Gelakte gegevens_linkhref_1mailto:DienstpostbusDatalekkenDoo@minvws.nl2025-09-01 12:32:56
About_Gelakte gegevensKomt u in dit document gegevens tegen waarvan u denkt dat deze gelakt hadden moeten worden? Of is het document slecht leesbaar? Laat het ons weten2025-09-01 12:32:56
document_SectionHistory12025-06-22 23:45:23
About_Documentnummer12458812025-06-22 23:45:23
About_BeoordelingOpenbaarmaking2025-06-22 23:45:23
About_Gelakte gegevensKomt u in dit document gegevens tegen waarvan u denkt dat deze gelakt hadden moeten worden? Of is het document slecht leesbaar? Laat het ons weten.2025-06-22 23:45:23
About_Gelakte gegevens_linkhref_1mailto:_dienstpostbusWoo-corona-ondersteuning@minvws.nl?subject=Opmerking over AEs na AstraZeneca.docx (documentnummer 1eec1b43-3849-6740-9d1c-bb3705657b16)2025-06-22 23:45:23
About_Gelakte gegevens_linkname_1Laat het ons weten2025-06-22 23:45:23
document_SectionRelated12025-06-22 23:45:23
document_SectionRequest12025-06-22 23:45:23
Request_Onderdeel vanWoo-deelbesluit aangaande Vaccinaties en Medicatie over de periode maart 20212025-06-22 23:45:23
Request_Onderdeel van_linkhref_1https://open.minvws.nl/dossier/VWS-WOO/3661708-1052463-pdo2025-06-22 23:45:23
Request_Onderdeel van_linkname_1Woo-deelbesluit aangaande Vaccinaties en Medicatie over de periode maart 20212025-06-22 23:45:23
Request_Samenvatting verzoekDe minister van Volksgezondheid, Welzijn en Sport heeft op 23 november 2023 een besluit genomen op verzoeken in het kader van de Wet open overheid. Het besluit betreft openbaarmaking van documenten die betrekking hebben op informatie aangaande Vaccinaties & Medicatie maart 2021.2025-06-22 23:45:23
Request_PeriodeMaart 20212025-06-22 23:45:23
Request_Type besluitWoo-besluit2025-06-22 23:45:23
Request_Datum besluit23 november 20232025-06-22 23:45:23
Request_Omvang openbaarmaking15.961 documenten, 29.047 pagina's Inventarislijst2025-06-22 23:45:23
Request_Omvang openbaarmaking_documenten15.9612025-06-22 23:45:23
Request_Omvang openbaarmaking_paginas29.0472025-06-22 23:45:23
Request_Omvang openbaarmaking_linkhref_1https://open.minvws.nl/dossier/VWS-WOO/3661708-1052463-pdo/file/download/inventory2025-06-22 23:45:23
Request_Omvang openbaarmaking_linkname_1Inventarislijst2025-06-22 23:45:23
document_documentNameAEs na AstraZeneca.docx2025-06-22 23:45:23
document_documentTypeWord-document2025-06-22 23:45:23
document_documentPublicationDate2021-03-112025-06-22 23:45:23
document_documentNumberVWS-WOO-08-12458812025-06-22 23:45:23
document_SectionDownloadButton02025-06-22 23:45:23
document_SectionHTMLDataDivs42025-06-22 23:45:23
document_SectionAbout12025-06-22 23:45:23
About_Datum document11 maart 20212025-06-22 23:45:23
About_Type bronbestandWord-document, 4 pagina's2025-06-22 23:45:23
About_Type bronbestand_paginas42025-06-22 23:45:23
About_Download alsPDF (1.92 MB)2025-06-22 23:45:23
History Datum_130 mei 2024 19:182025-06-21 06:28:01
History Actie_3Bronbestand vervangen (pdf, 1.92 MB)2025-06-21 06:28:01
History Datum_430 mei 2024 18:212025-06-21 06:28:01
History Actie_4Bronbestand vervangen (pdf, 1.92 MB)2025-06-21 06:28:01
History Datum_530 mei 2024 16:512025-06-21 06:28:01
History Actie_5Bronbestand vervangen (pdf, 1.92 MB)2025-06-21 06:28:01
History Datum_630 mei 2024 16:372025-06-21 06:28:01
History Actie_6Bronbestand vervangen (pdf, 1.92 MB)2025-06-21 06:28:01
History Datum_730 mei 2024 15:032025-06-21 06:28:01
History Actie_7Bronbestand vervangen (pdf, 1.92 MB)2025-06-21 06:28:01
History Datum_830 mei 2024 14:512025-06-21 06:28:01
History Actie_8Bronbestand toegevoegd (pdf, 1.92 MB)2025-06-21 06:28:01
History Datum_230 mei 2024 19:142025-06-21 06:28:01
History Actie_1Bronbestand vervangen (pdf, 1.92 MB)2025-06-21 06:28:01
History Datum_330 mei 2024 18:362025-06-21 06:28:01
History Actie_2Bronbestand vervangen (pdf, 1.92 MB)2025-06-21 06:28:01
DocumentDownload_linknameDownload (pdf, 1.92 MB)2025-04-19 21:08:22
DocumentDownload_linkhrefhttps://open.minvws.nl/dossier/VWS-WOO/3661708-1052463-pdo/file/download/document/1eec1b43-3849-6740-9d1c-bb3705657b162025-04-19 21:08:22
DocumentDownload_proposed_filename (lokale kopie)VWS-WOO-08-1245881.pdf2025-04-19 21:08:22

Archiefversies (6 rijen)

Archiefrij 1 — 2025-09-07 17:26:29
fromFile: folder_import
fromFilePath: /volume3/websites/openrijksoverheid/documenten_files/VWS-WOO-08-1245881.pdf
documentName: VWS-WOO-08-1245881.pdf
documentType: pdf
documentCompressedSize: 0
documentSize: 2018198
documentCompressRatio: 0
documentDateModified: 2025-09-07 17:26:29
dossierReference: leeg!
dossierReferenceAlias: leeg!
createdDate: 2025-09-07 17:26:29
lastSeen: 2025-09-07 17:26:29
text: 1245881 Data from clinical trials The most frequently reported adverse reactions after vaccination with AstraZeneca were injectionsite tenderness (63.7%); injection site pain (54.2%), headache (52.6%), fatigue (53.1%); myalgia (44.0%), malaise (44.2%); pyrexia (includes feverishness [33.6%] and feve...
noTextDate: leeg!
ocrText: leeg!
documentIndicatedDate: leeg!
documentIndicatedDateCorrected: leeg!
documentMailAddresses: leeg!
documentMailAdresses: leeg!
digestSHA256: 21cf56fe0b4d7ff6c395cc993edb10ca08238c20ca44f6fbfda2b18dcd62fee1
documentDate: leeg!
ModifiedDate: 2025-12-10 19:41:04.555019+00
Id: folder_import_49242_0e7647aa594a5c8965b8edf7c6010dbe
textDigestSHA256: def2bd5b187f464142e849eb692c8ea6e6491d619c67ed3631c0117f805a24f8
ocrTextDigestSHA256: leeg!
extractedId: VWS-WOO-08-1245881
Archiefrij 2 — 2025-09-04 17:12:23
fromFile: VWS-WOO-3661708-1052463-pdo-1f026c98-ad58-69b6-b436-65673e0af118.zip
fromFilePath: ../../archieven_files/VWS-WOO-3661708-1052463-pdo-1f026c98-ad58-69b6-b436-65673e0af118.zip
documentName: VWS-WOO-08-1245881.pdf
documentType: pdf
documentCompressedSize: 1389738
documentSize: 2018198
documentCompressRatio: 68.86033976844689
documentDateModified: 2025-05-01 20:31:08
dossierReference: leeg!
dossierReferenceAlias: leeg!
createdDate: 2025-09-04 17:12:23
lastSeen: 2025-09-04 17:12:23
text: 1245881 Data from clinical trials The most frequently reported adverse reactions after vaccination with AstraZeneca were injection site tenderness (63.7%); injection site pain (54.2%), headache (52.6%), fatigue (53.1%); myalgia (44.0%), malaise (44.2%); pyrexia (includes feverishness [33.6...
noTextDate: leeg!
ocrText: 1227720 Artikel ArtikeIType, ArtikelFarmaceut ArtikelDescription ArtikelCategorie ArtikelAantal ArtikelEenheid, ArtikelHoeveelheid, ArtikelHoeveelheid Flacons,ArtikelHoeveelheidDosesPerTray ArtikelHoeveelheidDoses, ArtikelAfnemer ArtikelAfnemerGroep, ArtikelAfgiftedatum , ArtikelStatus, ArtikelAfze...
documentIndicatedDate: leeg!
documentIndicatedDateCorrected: leeg!
documentMailAddresses: leeg!
documentMailAdresses: leeg!
digestSHA256: 21cf56fe0b4d7ff6c395cc993edb10ca08238c20ca44f6fbfda2b18dcd62fee1
documentDate: leeg!
ModifiedDate: 2025-12-10 19:42:10.749631+00
Id: VWS-WOO-3661708-1052463-pdo-1f026c98-ad58-69b6-b436-65673e0af118.zip_1493
textDigestSHA256: 73731aba7b6b39b333c4fa7f53ba2bbe83ca1e8283575d6da0384217ab9d919a
ocrTextDigestSHA256: cbb318e36bc801b51a4e835f266ccf9e2f2591f7587882f9cceab6e8131f83fb
extractedId: VWS-WOO-08-1245881
Archiefrij 3 — 2025-09-04 17:10:20
fromFile: VWS-WOO-3661708-1052463-pdo-1f019da5-31c3-6fd4-91a7-fda7571a98e0.zip
fromFilePath: ../../archieven_files/VWS-WOO-3661708-1052463-pdo-1f019da5-31c3-6fd4-91a7-fda7571a98e0.zip
documentName: VWS-WOO-08-1245881.pdf
documentType: pdf
documentCompressedSize: 1389738
documentSize: 2018198
documentCompressRatio: 68.86033976844689
documentDateModified: 2025-05-01 20:31:08
dossierReference: leeg!
dossierReferenceAlias: leeg!
createdDate: 2025-09-04 17:10:20
lastSeen: 2025-09-04 17:10:20
text: 1245881 Data from clinical trials The most frequently reported adverse reactions after vaccination with AstraZeneca were injection site tenderness (63.7%); injection site pain (54.2%), headache (52.6%), fatigue (53.1%); myalgia (44.0%), malaise (44.2%); pyrexia (includes feverishness [33.6...
noTextDate: leeg!
ocrText: isoweek-2021 isoweek-2022 |Ct-waarde 2022-09 2022-09 2022-09 2022-09 2022-09 2022-09 2022-09 2022-09 2022-09 2022-09 2022-09 2022-09 2022-09 2022-09 2022-09 2022-09 2022-09 2022-09 2022-09 2022-09 2022-09 2022-09 2022-09 2022-09 2022-09 2022-09 2022-09 2022-09 2022-09 2022-...
documentIndicatedDate: leeg!
documentIndicatedDateCorrected: leeg!
documentMailAddresses: leeg!
documentMailAdresses: leeg!
digestSHA256: 21cf56fe0b4d7ff6c395cc993edb10ca08238c20ca44f6fbfda2b18dcd62fee1
documentDate: leeg!
ModifiedDate: 2025-12-10 19:42:10.749631+00
Id: VWS-WOO-3661708-1052463-pdo-1f019da5-31c3-6fd4-91a7-fda7571a98e0.zip_1493
textDigestSHA256: 73731aba7b6b39b333c4fa7f53ba2bbe83ca1e8283575d6da0384217ab9d919a
ocrTextDigestSHA256: 34ea7743594f08b217c2e155c1f4035ef17e172d69327d310aa73507055b967b
extractedId: VWS-WOO-08-1245881
Archiefrij 4 — 2025-03-18 09:30:26
fromFile: 2024.075-VWS-WOO-3661708-1052463-pdo.zip
fromFilePath: Z:\ARCHIEF WOO Documenten\archieven_files\2024.075-VWS-WOO-3661708-1052463-pdo.zip
documentName: VWS-WOO-08-1245881-AEs_na_AstraZeneca.docx.pdf
documentType: pdf
documentCompressedSize: 1386385
documentSize: 2018198
documentCompressRatio: 68.6942014609072
documentDateModified: 2024-10-25 13:30:26
dossierReference: leeg!
dossierReferenceAlias: leeg!
createdDate: 2025-03-18 09:30:26
lastSeen: 2025-03-18 09:30:26
text: 1245881 Data from clinical trials The most frequently reported adverse reactions after vaccination with AstraZeneca were injectionsite tenderness (63.7%); injection site pain (54.2%), headache (52.6%), fatigue (53.1%); myalgia (44.0%), malaise (44.2%); pyrexia (includes feverishness [33.6%] and feve...
noTextDate: leeg!
ocrText: leeg!
documentIndicatedDate: leeg!
documentIndicatedDateCorrected: leeg!
documentMailAddresses: leeg!
documentMailAdresses: leeg!
digestSHA256: def2bd5b187f464142e849eb692c8ea6e6491d619c67ed3631c0117f805a24f8
documentDate: leeg!
ModifiedDate: 2025-12-10 19:42:20.178639+00
Id: 355303
textDigestSHA256: def2bd5b187f464142e849eb692c8ea6e6491d619c67ed3631c0117f805a24f8
ocrTextDigestSHA256: leeg!
extractedId: VWS-WOO-08-1245881
Archiefrij 5 — 2025-02-27 09:25:06
fromFile: 2022.252-VWS-WOO-3661708-1052463-pdo.zip
fromFilePath: Z:\ARCHIEF WOO Documenten\archieven_files\2022.252-VWS-WOO-3661708-1052463-pdo.zip
documentName: VWS-WOO-08-1245881-AEs_na_AstraZeneca.docx.pdf
documentType: pdf
documentCompressedSize: 1386385
documentSize: 2018198
documentCompressRatio: 68.6942014609072
documentDateModified: 2024-10-25 13:30:26
dossierReference: leeg!
dossierReferenceAlias: leeg!
createdDate: 2025-02-27 09:25:06
lastSeen: 2025-02-27 09:25:06
text: 1245881 Data from clinical trials The most frequently reported adverse reactions after vaccination with AstraZeneca were injectionsite tenderness (63.7%); injection site pain (54.2%), headache (52.6%), fatigue (53.1%); myalgia (44.0%), malaise (44.2%); pyrexia (includes feverishness [33.6%] and feve...
noTextDate: leeg!
ocrText: leeg!
documentIndicatedDate: leeg!
documentIndicatedDateCorrected: leeg!
documentMailAddresses: leeg!
documentMailAdresses: leeg!
digestSHA256: def2bd5b187f464142e849eb692c8ea6e6491d619c67ed3631c0117f805a24f8
documentDate: leeg!
ModifiedDate: 2025-12-10 19:41:04.555019+00
Id: 268473
textDigestSHA256: def2bd5b187f464142e849eb692c8ea6e6491d619c67ed3631c0117f805a24f8
ocrTextDigestSHA256: leeg!
extractedId: VWS-WOO-08-1245881
Archiefrij 6 — 2025-02-18 12:18:04
fromFile: Besluit__dossier_nr_-8b6498f524850c599dea15620ecff89d59609350ff716d119d38634615d4d862.zip
fromFilePath: Z:\ARCHIEF WOO Documenten\archieven_files\Besluit__dossier_nr_-8b6498f524850c599dea15620ecff89d59609350ff716d119d38634615d4d862.zip
documentName: VWS-WOO-08-1245881-AEs_na_AstraZeneca.docx.pdf
documentType: pdf
documentCompressedSize: 1386385
documentSize: 2018198
documentCompressRatio: 68.6942014609072
documentDateModified: 2024-10-25 13:30:26
dossierReference: leeg!
dossierReferenceAlias: leeg!
createdDate: 2025-02-18 12:18:04
lastSeen: 2025-02-18 12:18:04
text: 1245881 Data from clinical trials The most frequently reported adverse reactions after vaccination with AstraZeneca were injectionsite tenderness (63.7%); injection site pain (54.2%), headache (52.6%), fatigue (53.1%); myalgia (44.0%), malaise (44.2%); pyrexia (includes feverishness [33.6%] and feve...
noTextDate: leeg!
ocrText: leeg!
documentIndicatedDate: leeg!
documentIndicatedDateCorrected: leeg!
documentMailAddresses: leeg!
documentMailAdresses: leeg!
digestSHA256: def2bd5b187f464142e849eb692c8ea6e6491d619c67ed3631c0117f805a24f8
documentDate: leeg!
ModifiedDate: 2025-12-10 19:41:04.555019+00
Id: 57609
textDigestSHA256: def2bd5b187f464142e849eb692c8ea6e6491d619c67ed3631c0117f805a24f8
ocrTextDigestSHA256: leeg!
extractedId: VWS-WOO-08-1245881

(dit is ook een speeltuin)